A5101685517- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Mesenchymal stem cell research
- Immunodeficiency and Autoimmune Disorders
- Childhood Cancer Survivors' Quality of Life
- Hemoglobinopathies and Related Disorders
- Polyomavirus and related diseases
- Chronic Lymphocytic Leukemia Research
- Cytomegalovirus and herpesvirus research
- Renal Transplantation Outcomes and Treatments
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Blood groups and transfusion
- Parvovirus B19 Infection Studies
- Neonatal Health and Biochemistry
- Oral health in cancer treatment
- Chronic Myeloid Leukemia Treatments
- Bone and Joint Diseases
- Neuroblastoma Research and Treatments
- Transplantation: Methods and Outcomes
- Hematological disorders and diagnostics
- Metabolism and Genetic Disorders
- Pharmacogenetics and Drug Metabolism
- Structural Engineering and Vibration Analysis
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2018-2025
Hospital Israelita Albert Einstein
2011-2025
Instituto de Terapia Integrada e Oriental
2025
Universidade de São Paulo
2011-2025
Grupo Hospitalar Conceição
2025
European Organisation for Rare Diseases
2014
Universidade Brasil
2011
Hôpital Necker-Enfants Malades
2007
Hôpital Saint-Louis
2006-2007
Umbilical cord blood transplant recipients are exposed to an increased risk of graft failure, a complication leading higher rate transplant-related mortality. The decision and timing offer second after failure is challenging. With the aim addressing this issue, we analyzed engraftment kinetics outcomes 1268 patients (73% children) with acute leukemia (64% lymphoblastic leukemia, 36% myeloid leukemia) in remission who underwent single-unit umbilical transplantation myeloablative conditioning...
Omidubicel is an umbilical cord blood (UCB)-derived ex vivo-expanded cellular therapy product that has demonstrated faster engraftment and fewer infections compared with unmanipulated UCB in allogeneic hematopoietic cell transplantation. Although the early benefits of omidubicel have been established, long-term outcomes remain unknown. We report on a planned pooled analysis 5 multicenter clinical trials including 105 patients hematologic malignancies or sickle hemoglobinopathy who underwent...
Background ARPC1B deficiency leads to a combined immunodeficiency characterized by early clinical onset, recurrent infections, and platelet abnormalities with bleeding tendency. Although most patients mutations tolerate transplant conditioning, high rate of resolution, there is lack studies comparing the outcome quality life undergoing transplantation or treated conservatively. The aim study compare managed conservatively HSCT assessing life. Methods was approved ESID, EBMT, CIS inborn error...
Abstract Graft failure (GF) can be a fatal complication following haematopoietic stem cell transplantation (HSCT). We report four patients who developed early GF after unrelated HSCT and subsequently received double cord blood transplant (dUCBT) reduced‐intensity conditioning, at median 15 d the decision to perform second transplant. Neutrophil recovery was observed in all between day +15 +31 with full donor chimaerism of one unit. Acute GVHD grades II–IV three patients. Three are alive, 12...
Abstract In this study, we report on major MRD or URD BMT outcomes in pediatric patients with SAA Brazil. This was a retrospective which included 106 ≤18 years old who received first for SAA. All bone marrow as graft source from an (n = 69) 37). Conditioning regimen non‐myeloablative 73.6% of cases, and GVHD prophylaxis comprised calcineurin inhibitor plus methotrexate 89.6% patients. After median follow‐up 4.5 after BMT, 81 are alive, 4‐year OS 77% no statistically significant difference...
The survival rates of children with high-risk acute myeloid leukemia (AML) treated hematopoietic stem cell transplant (HSCT) range from 60% to 70% in high-income countries. corresponding rate for Brazilian AML who undergo HSCT is unknown. We conducted a retrospective analysis 114 underwent between 2008 and 2012 at institutions participating the Pediatric Bone Marrow Transplant Working Group. At transplant, 38% were first complete remission (CR1), 37% CR2, 25% CR3+ or had persistent disease....
Este artigo traz informações sobre o comportamento nas primeiras idades de um concreto alta resistência, produzido com cimento resistência inicial, lançado e adensado em ambientes submetidos a vibrações, como obras pontes rodovias. Apresenta-se programa experimental desenvolvido, descrevendo desde moldagem dos corpos-de-prova, sob ação vibrações similares às induzidas pelo tráfego, até os ensaios caracterização mecânica aderência aço-concreto. Os resultados experimentais indicam que...
Abstract The choice of alternative donors for HCT patients without an HLA‐matched related donor depends on several factors. We compared major outcomes in 212 consecutive children transplanted at 11 centers Brazil acute leukemia or MDS from unrelated (MUD, n = 95), mismatched (MMUD, 47) umbilical cord blood (UCB, 70). Most had ALL (61%), bone marrow (57%) as the graft source and 95% received a MAC regimen. 3‐year OS probability were 57, 55, 37% after MUD, MMUD, UCB, respectively (HR 1.68,...
Abstract Busulfan is given in the conditioning regimens preceding hematopoietic stem cell transplantation (HSCT), and plasma levels can be monitored. A targeted, individualized systemic exposure (SE) dose achieved by calculating area under concentration versus time curve (AUC). The objective of this study was to determine a cutoff value for safety AUC busulfan patients undergoing HSCT. total 149 consecutive HSCT were studied. After an oral test busulfan, we set target doses 4000, 5000, or...
Abstract Hematopoietic stem cell transplantation (HSCT) is an established treatment for selected patients with inborn errors of metabolism. In this first report from the PDWP-SBTMO, we included 105 transplanted between 1988 and 2021 across six Brazilian HSCT centers. The most prevalent diseases were X-linked adrenoleukodystrophy(n=61) mucopolysaccharidosis (type I n=20; type II n=10), a median age at 8.7years 2.1years, respectively. Most conditioning regimens myeloablative busulfan-based....
Background: Allogeneic stem cell transplantation (allo-HSCT) is a high-cost procedure, mainly represented by length of hospitalization, as well hospital readmissions. Different types alternative donor may impact differently on the costs this procedure. Objective: To evaluate source, type transplant and age at time hospitalization in different allo-HSCT. Method: A retrospective analysis consecutive patients submitted to allo-HSCT our institution from Jan/2010 Jan/2017. Results: 188 were...